Brean Murray Raises Price Target on Ardea (RDEA) to $23; Sees Phase 2b Trials on RDEA594 Proving It Is a 'Safe and Effective Drug'
Tweet Send to a Friend
Brean Murray raised its 12-month price target on shares of Ardea Biosciences (Nasdaq: RDEA) from $19 to $23 this morning ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
